AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|AAPL342.37-1.80 (-0.52%) ▼|ABBV291.31+3.07 (+1.07%) ▲|ABT109.93-3.67 (-3.23%) ▼|ACN260.50-4.66 (-1.76%) ▼|ADBE239.30-7.14 (-2.90%) ▼|AMAT332.72+13.47 (+4.22%) ▲|AMD449.04+44.64 (+11.04%) ▲|AMGN460.42+0.14 (+0.03%) ▲|AMT188.79-5.20 (-2.68%) ▼|AMZN259.30-0.91 (-0.35%) ▼|AVGO293.69+2.16 (+0.74%) ▲|AXP320.99-3.98 (-1.22%) ▼|BA173.40+0.90 (+0.52%) ▲|BAC49.42-0.34 (-0.68%) ▼|BKNG160.67-8.06 (-4.77%) ▼|BLK1,178.87+8.20 (+0.70%) ▲|BMY62.14-0.99 (-1.57%) ▼|BNY147.72+0.23 (+0.16%) ▲|BRK-B570.89-1.44 (-0.25%) ▼|C119.05+0.60 (+0.51%) ▲|CAT558.63+4.99 (+0.90%) ▲|CL96.56-2.13 (-2.16%) ▼|CMCSA24.39-0.56 (-2.24%) ▼|COF201.87-1.97 (-0.97%) ▼|COP136.27+0.81 (+0.60%) ▲|COST1,053.56-12.03 (-1.13%) ▼|CRM213.65-8.76 (-3.94%) ▼|CSCO93.85-1.87 (-1.95%) ▼|CVS83.85+2.52 (+3.10%) ▲|CVX212.61-0.32 (-0.15%) ▼|DE671.65+8.34 (+1.26%) ▲|DHR230.25+3.91 (+1.73%) ▲|DIS116.75-0.47 (-0.40%) ▼|DUK127.78-2.30 (-1.77%) ▼|EMR162.35-0.26 (-0.16%) ▼|FDX308.14-8.66 (-2.73%) ▼|GD354.06-2.29 (-0.64%) ▼|GE323.24+8.51 (+2.70%) ▲|GEV774.11+3.60 (+0.47%) ▲|GILD166.89-0.68 (-0.41%) ▼|GM86.16-3.17 (-3.55%) ▼|GOOG283.93+2.19 (+0.78%) ▲|GOOGL284.78+2.21 (+0.78%) ▲|GS865.82-3.13 (-0.36%) ▼|HD343.47-6.47 (-1.85%) ▼|HON220.05+4.27 (+1.98%) ▲|IBM245.00-2.11 (-0.85%) ▼|INTC56.28+4.03 (+7.71%) ▲|INTU341.50-13.34 (-3.76%) ▼|ISRG452.80-15.72 (-3.36%) ▼|JNJ276.22+3.90 (+1.43%) ▲|JPM334.49-2.85 (-0.84%) ▼|KO95.67-0.06 (-0.06%) ▼|LIN515.25-5.98 (-1.15%) ▼|LLY1,354.00-10.73 (-0.79%) ▼|LMT567.08-9.08 (-1.58%) ▼|LOW224.55-2.69 (-1.18%) ▼|LRCX200.44+15.24 (+8.23%) ▲|MA652.70-3.22 (-0.49%) ▼|MCD276.52-1.52 (-0.55%) ▼|MDLZ66.02-0.80 (-1.20%) ▼|MDT101.80-3.04 (-2.90%) ▼|META610.15+5.07 (+0.84%) ▲|MMM185.15-2.62 (-1.40%) ▼|MO76.12-1.46 (-1.88%) ▼|MRK146.73-0.21 (-0.14%) ▼|MS181.44-1.00 (-0.55%) ▼|MSFT530.61-5.32 (-0.99%) ▼|MU690.00+33.61 (+5.12%) ▲|NEE86.95-1.30 (-1.47%) ▼|NFLX63.41-2.15 (-3.28%) ▼|NKE38.59-0.97 (-2.45%) ▼|NOW101.97-0.39 (-0.38%) ▼|NVDA186.64+5.04 (+2.78%) ▲|ORCL116.10+0.94 (+0.82%) ▲|PEP141.34-1.37 (-0.96%) ▼|PFE29.39-0.06 (-0.20%) ▼|PG165.40-1.70 (-1.02%) ▼|PLTR160.38+5.39 (+3.48%) ▲|PM197.88-3.62 (-1.80%) ▼|QCOM165.41+8.66 (+5.52%) ▲|RTX189.53-2.35 (-1.22%) ▼|SBUX105.41-0.75 (-0.71%) ▼|SCHW91.49-1.09 (-1.18%) ▼|SO92.34-1.00 (-1.07%) ▼|SPG228.42+1.87 (+0.83%) ▲|T21.63-0.19 (-0.87%) ▼|TMO694.76+17.82 (+2.63%) ▲|TMUS162.01+1.42 (+0.88%) ▲|TSLA358.22+14.53 (+4.23%) ▲|TXN277.36-0.79 (-0.28%) ▼|UBER68.59-0.19 (-0.28%) ▼|UNH394.15-1.57 (-0.40%) ▼|UNP290.16-7.79 (-2.61%) ▼|UPS108.30-2.74 (-2.47%) ▼|USB59.45-0.30 (-0.50%) ▼|V422.65+0.06 (+0.01%) ▲|VZ45.69-0.43 (-0.93%) ▼|WFC83.94-0.36 (-0.43%) ▼|WMT125.52-2.20 (-1.72%) ▼|XOM165.87+0.57 (+0.34%) ▲|
11.3 C
New York
Monday, November 9, 2026

Tag: health

newsFORsourcecompanycontentinformationreleases1market

Extendicare Announces Renewal of Normal Course Issuer Bid

MARKHAM, Ontario, June 26, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that the Toronto Stock Exchange (the “TSX”) has approved the renewal of Extendicare’s normal course issuer bid (“NCIB”). Under the terms of the NCIB, the Company may purchase for cancellation up to 7,281,193 of its common shares (the “Common Shares”), representing 10% of its public float of issued and outstanding Common Shares. As at June 20, 2025, there were 83,817,909 Common Shares issued and outstanding and the public float was 72,811,939 Common Shares, calculated in accordance with the rules of the TSX.

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Eisenhower Fellowships Names 2025 USA Fellows

PHILADELPHIA, June 26, 2025 /PRNewswire/ -- Eisenhower Fellowships (EF) has selected nine exceptional young American leaders from diverse professional fields for its prestigious 2025...

ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

Ahold Delhaize USA Services, LLC Provides Update on Cybersecurity Issue

SALISBURY, N.C., June 26, 2025 (GLOBE NEWSWIRE) -- Ahold Delhaize USA Services today announced an update about the cybersecurity issue that was previously disclosed last year.

Teva Releases Q2 2025 Aide Memoire

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website.

Colorado Scenthound Locations Partner with Humane Colorado to Give Adopted Dogs a “Clean Start”

DENVER, June 26, 2025 /PRNewswire/ -- All Colorado Scenthound locations have joined together to launch a new partnership with Humane Colorado, formerly the Dumb...

Alto Ingredients, Inc. Names Gilbert Nathan Chair, Dianne Nury Vice-Chair and Elects Two New Directors

- Jeremy T. Bezdek is a seasoned expert in energy transition -

EVA Pharma and BioPharma Town – Qiantang District, Hangzhou Sign a Strategic Cooperation Agreement

EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office 
EVA Pharma Deepens Its Roots in China’s Thriving Biopharmaceutical Ecosystem with The Inauguration of Its Hangzhou Office

Ultima Genomics Selected to Support the World’s Largest Proteomics Studies to Date Led by Regeneron Genetics Center

FREMONT, Calif., June 26, 2025 /PRNewswire/ -- Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that its UG 100 ™ sequencing platform...

Leading Kefir-Maker Lifeway Foods’ Berry Blast Probiotic Smoothie + Collagen Selected as a Good Housekeeping 2025 Snack Awards Winner

MORTON GROVE, Ill., June 26, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ: LWAY), a leading U.S. supplier of kefir and fermented probiotic products that...

Dr. Irfan Atcha and New Teeth Chicago™ Join The Alston as Founding Members, Welcoming the Private Club to River North

Dr. Irfan Atcha, nationally renowned dental implant surgeon and founder of New Teeth Chicago™, has officially joined The Alston, Chicago's exclusive new private member...

Global Cancer Immunotherapy Market Projected to Reach $247 Billion by 2029, Driven by 11.4% CAGR

"Harnessing the Power of the Immune System: How Cancer Immunotherapy and Oncolytic Virology Are Reshaping the Future of Oncology in a Digitally Driven Era" BOSTON,...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsHealth

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers